Distribution of adverse events in 2 treatment groups
. | Lower-risk . | Higher-risk . |
|---|---|---|
| No. | 117 | 130 |
| Induction failure | 1 | 4 |
| Relapse | ||
| Bone marrow | 8 | 11 |
| CNS only | 1 | 3 |
| CNS + bone marrow | 1 | 1 |
| CNS + mediastinal | 0 | 1 |
| CNS + ocular | 0 | 1 |
| Testicular only | 0 | 1 |
| Ocular | 0 | 1 |
| Second malignancies | 2 | 6 |
| Deaths in remission | 2 | 5 |
| Patients in CCR | 102 | 96 |
. | Lower-risk . | Higher-risk . |
|---|---|---|
| No. | 117 | 130 |
| Induction failure | 1 | 4 |
| Relapse | ||
| Bone marrow | 8 | 11 |
| CNS only | 1 | 3 |
| CNS + bone marrow | 1 | 1 |
| CNS + mediastinal | 0 | 1 |
| CNS + ocular | 0 | 1 |
| Testicular only | 0 | 1 |
| Ocular | 0 | 1 |
| Second malignancies | 2 | 6 |
| Deaths in remission | 2 | 5 |
| Patients in CCR | 102 | 96 |